Anifrolumab Phase III Trial Meets Primary Endpoint in Systemic Lupus Erythematosus

29 August 2019 -- AstraZeneca today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a statistically-significant and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials